|
|
 |
|
|
 |
AMORCYTE, INC OPENS CELL THERAPY TRIAL FOR CARDIOVASCULAR DISEASE AT EMORY UNIVERSITY
Initial Study to Focus on Safety, Efficacy, and Mechanism of Action
HACKENSACK, New Jersey - (June 5, 2006) - Amorcyte Inc (Amorcyte), a privately funded cell therapy company developing products to treat cardiovascular disease, announced today that its Phase I clinical trial is now open at Emory University School of Medicine, under Arshed A. Quyyumi, M.D., FRCP, FACC, Professor of Medicine, Cardiology, and is expected to open in another center within 90 days.
"In many ways this is an important and unique Phase I trial for the developing field of cell therapies for cardiovascular disease", states Dr. Quyyumi. "In addition to safety, this trial will assess the effect of stem cell dose on definitive clinical endpoints following administration after myocardial infarction."
"The trial end points should facilitate rapid performance of a Phase II and subsequent trials if safety and biologic activity is observed" states Dr. Thomas Moss, Amorcyte's Chief Medical Officer. "We have garnered significant support and contributions from a wide variety of cell therapy and cardiology experts who have advised us on this development strategy."
It is estimated there are approximately 1.1 million instances of acute myocardial infarction, 12 million cases of chronic ischemia, and 5 million occurrences of congestive heart failure in the United States per year. A significant percentage of these patients are in need of additional therapies to ameliorate the symptoms of their disease. Products including AMR-001 are now under active investigation to determine safety and potential biologic activity.
Amorcyte expects to enroll its first patients in June and is actively recruiting patients for the trial.
|
|
|
